ClinicalTrials.gov
ClinicalTrials.gov Menu

Reduction of Asthma Exacerbation Rate in Children by Non-invasive Monitoring of Inflammatory Markers in Exhaled Breath (Condensate): the RASTER Study (RASTER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01239238
Recruitment Status : Completed
First Posted : November 11, 2010
Last Update Posted : November 15, 2013
Sponsor:
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by (Responsible Party):
Maastricht University Medical Center

Brief Summary:
The purpose of the present proposal was to investigate the predictive properties of markers in exhaled breath to predict an asthma exacerbation. In addition, the reliability of home monitor assessments to measure asthma control will be examined.

Condition or disease
Asthma Children Home Monitoring Exhaled Breath Condensate Non-invasive Inflammatory Markers Volatile Organic Compounds

Study Type : Observational
Actual Enrollment : 102 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Reduction of Asthma Exacerbation Rate in Children by Non-invasive Monitoring of Inflammatory Markers in Exhaled Breath (Condensate): the RASTER Study
Study Start Date : November 2010
Actual Primary Completion Date : December 2012
Actual Study Completion Date : March 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Group/Cohort
Care as usual
Therapy is guided based on symptoms and lung function. Assessments: home monitoring, symptoms, lung function, FeNO, asthma control, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.



Primary Outcome Measures :
  1. number of exacerbations [ Time Frame: 1 year ]
    increase of asthma symptoms, use of short b2-agonists, drop in FEV1% of maximum personal value.

  2. asthma control [ Time Frame: 1 year ]
    asthma control questionnaire

  3. Quality of life [ Time Frame: 1 year ]
    Asthma Quality of Life questionnaire for children


Secondary Outcome Measures :
  1. cost-effectiveness [ Time Frame: 1 year ]
    incremental cost per exacerbation prevented



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
This study is carried out in two hospitals in the Netherlands (Maastricht University Medical Centre, Maastricht; and Orbis Medical Centre, Sittard).
Criteria

Inclusion Criteria:

  1. already known with a diagnosis of asthma during at least 6 months
  2. age between 6 and 17 years
  3. reversibility to a bronchodilator (increase in FEV1 > 9% of predicted value and/or
  4. bronchial hyperresponsiveness to histamine < 8 mg/ml.

Exclusion Criteria:

  1. cardiac abnormalities
  2. mental retardation, congenital abnormalities or existence of a syndrome
  3. active smoking
  4. no technical satisfactory performance of measurements
  5. no phone line or internet assess available at home.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01239238


Locations
Netherlands
Maastricht University Hospital
Maastricht, Netherlands, 6202 AZ
Orbis Medical Centre
Sittard, Netherlands
Sponsors and Collaborators
Maastricht University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development
Investigators
Principal Investigator: Edward Dompeling, PhD MD Maastricht UMC

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT01239238     History of Changes
Other Study ID Numbers: 10-2-064
First Posted: November 11, 2010    Key Record Dates
Last Update Posted: November 15, 2013
Last Verified: November 2013

Keywords provided by Maastricht University Medical Center:
asthma
children
home monitoring
exhaled breath condensate
non-invasive inflammatory markers
volatile organic compounds

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases